No difference in clinical outcomes with 81 mg vs. 325 mg aspirin in established CVD

Media formats available:

Can targeting of IL-6 lead to CV protection in CKD?
Can targeting of IL-6 lead to CV protection in CKD?
ACC.21
Can targeting of IL-6 lead to CV protection in CKD?
- Prof. Peter Libby, MD
Renal denervation as option for patients with hypertension despite medications
Renal denervation as option for patients with hypertension despite medications
ACC.21
Renal denervation as option for patients with hypertension despite medications
- Prof. Ajay Kirtane, MD
No superiority with NOAC compared to standard care following TAVI
No superiority with NOAC compared to standard care following TAVI
ACC.21
No superiority with NOAC compared to standard care following TAVI
- Jean-Philippe Collet, MD, PhD
Possible substitution of aspirin by P2Y12 inhibitor monotherapy one year after PCI
Possible substitution of aspirin by P2Y12 inhibitor monotherapy one year after PCI
ACC.21
Possible substitution of aspirin by P2Y12 inhibitor monotherapy one year after PCI
- Prof. Freek Verheugt, MD

PACE-CME